Figure 7

Assessment of Aβ oligomers. Western blot of brain homogenates labeled with A11 oligomer-specific antibody ( A ) and densitometric analysis of A11 immunoreactive oligomer specific bands (approximately 32 kDA and 28 kDa, in arbitrary O.D. units) showed a significant reduction in CpG ODN-treated Tg mice compared with control Tg mice in the 11–18 month study group (32 kDA, *p = 0.015; 28 kDa, *p = 0.023) ( B ). As further assessed by an ELISA specific to oligomeric Aβ, CpG ODN treatment led to a significant decrease in Aβ oligomers in both study groups (7–20 month study group, *p = 0.03; 11–18 study group, *p = 0.04) ( C , D ).